SPAGO Stock Overview
A clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Spago Nanomedical AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.31 |
| 52 Week High | kr0.73 |
| 52 Week Low | kr0.20 |
| Beta | 2.05 |
| 1 Month Change | 2.34% |
| 3 Month Change | 3.38% |
| 1 Year Change | -56.16% |
| 3 Year Change | -95.71% |
| 5 Year Change | -97.01% |
| Change since IPO | -97.81% |
Recent News & Updates
Recent updates
Most Shareholders Will Probably Agree With Spago Nanomedical AB (publ)'s (STO:SPAGO) CEO Compensation
Jun 04
We're Not Worried About Spago Nanomedical's (STO:SPAGO) Cash Burn
Sep 21We're Interested To See How Spago Nanomedical (STO:SPAGO) Uses Its Cash Hoard To Grow
May 26Loss-Making Spago Nanomedical AB (publ) (STO:SPAG) Set To Breakeven
Mar 30We're Hopeful That Spago Nanomedical (NGM:SPAG) Will Use Its Cash Wisely
Feb 03
Loss-Making Spago Nanomedical AB (publ) (NGM:SPAG) Expected To Breakeven In The Medium-Term
Dec 11Shareholder Returns
| SPAGO | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 10.1% | -0.8% | 0.03% |
| 1Y | -56.2% | 4.9% | 14.1% |
Return vs Industry: SPAGO underperformed the Swedish Biotechs industry which returned 4.9% over the past year.
Return vs Market: SPAGO underperformed the Swedish Market which returned 14.1% over the past year.
Price Volatility
| SPAGO volatility | |
|---|---|
| SPAGO Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 12.8% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: SPAGO's share price has been volatile over the past 3 months.
Volatility Over Time: SPAGO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 12 | Mats Hansen | spagonanomedical.se |
Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under Preclinical development stage. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014.
Spago Nanomedical AB (publ) Fundamentals Summary
| SPAGO fundamental statistics | |
|---|---|
| Market cap | kr106.55m |
| Earnings (TTM) | -kr34.41m |
| Revenue (TTM) | kr6.01m |
17.7x
P/S Ratio-3.1x
P/E RatioIs SPAGO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPAGO income statement (TTM) | |
|---|---|
| Revenue | kr6.01m |
| Cost of Revenue | kr16.92m |
| Gross Profit | -kr10.90m |
| Other Expenses | kr23.51m |
| Earnings | -kr34.41m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 21, 2024
| Earnings per share (EPS) | -0.099 |
| Gross Margin | -181.39% |
| Net Profit Margin | -572.41% |
| Debt/Equity Ratio | 0% |
How did SPAGO perform over the long term?
See historical performance and comparison